Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | BBU Momentum · Hungarian Utilization Rebound · 2026 Operating Profit Turnaround / 2026-03-18 Research
  • [IR] SK hynix (000660 / SKHY) – Q2 2024 Earnings Presentation / 2024-07-25 IR Room
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30 Research
  • [Research] Samsung SDI (006400) – Hana Securities | SDC Stake Monetization Pursuit · Up to KRW 11T Liquidity · Valuation Multiples Re-rating / 2026-02-20 Research
  • [IR] Samsung Electronics (005930) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room
  • [IR] SK hynix (000660 / SKHY) – Q1 2025 Earnings Presentation / 2025-04-24 IR Room
  • [Research] Samsung SDI (006400) – Shinhan Securities | North America ESS Surges · BBU Demand Expansion · Turnaround Visibility / 2026-04-20 Research
  • [Research] Samsung SDI (006400) – Hana Securities | Stepwise Loss Reduction · Strong ESS BBU Shipments · 4Q26 Turnaround / 2026-02-03 Research

[Research] SK hynix (000660 / SKHY) – Daishin | Capex Discipline · Multi-Year LTA · Shareholder Returns / 2026-01-30

Posted on January 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Daishin Securities

Analyst : Hyungkeun Ryu (RA: Jiwon Seo)

Investment Rating : BUY (Maintained)

Target Price : 1,250,000 KRW (Raised)

Core Momentum : Disciplined Capex is expected to prevent excessive capacity expansion during the memory super-cycle, while multi-year LTAs and prepayment-based contracts improve supply stability and cash-flow visibility, supporting stronger shareholder returns and corporate value.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 1,250,000 KRW (Based on Target P/B 4.0x, applying a 15% discount to Micron Technology’s 12m Fwd P/B on 2026F BPS, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 205.34 trillion KRW, Operating Profit 142.01 trillion KRW, Net Income 110.19 trillion KRW
  • EPS: 151,350 KRW (2026F)
  • Valuation Multiples: PER 3.4x, PBR 2.8x, ROE 63.4% (Based on 2026F)

🚀 2. [Market Opportunities & Business Outlook]

  • Key Management Message: Amid a memory super-cycle, 1) maintaining strict Capex discipline to avoid excessive expansion, and 2) advancing sales policy changes such as Multi-Year LTAs, deposits, and prepayments to enhance supply stability and corporate value.
  • Capex Outlook: 2026 Capex is projected to rise to the upper 30 trillion KRW range, but remains controlled at around 20% in capital intensity, making a sudden surge unlikely as investments center strictly on essential infrastructure.
  • Shareholder Returns & HBM: Leveraging unprecedented supply-demand imbalances to push forward with policies strengthening shareholder returns and securing growth capital, with potential ADR issuance via treasury share buybacks. HBM4 shipments are proceeding smoothly on schedule despite market concerns, reinforcing confidence in maintaining top-tier market share.
  • Industry Context: Reflecting a period where various efforts to restructure business operations overlap with ongoing initiatives for shareholder returns and enterprise value enhancement during the memory super-cycle.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as a company that maintains Capex discipline and pursues sales policy changes such as Multi-Year LTAs during the memory super-cycle, thereby establishing opportunities for corporate value enhancement and strengthened shareholder returns. The analyst highlights the management’s efforts to secure supply stability and drive value-up initiatives.

To verify this investment thesis, one should track whether 2026 Capex execution remains within controlled thresholds, if Multi-Year LTAs and deposits effectively contribute to supply stability and corporate value, and how HBM4 shipments and shareholder return policies unfold. These indicators can be monitored through upcoming quarterly earnings reports and regulatory disclosures via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30
Next Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · Operating Leverage · Shareholder Returns / 2026-01-30

Related Posts

  • [Research] Samsung Biologics (207940) – Yuanta Securities | US Site Acquisition · Biosecure Act Beneficiary · Plant 6 & Campus 3 Expansion / 2026-01-07 Research
  • [Research] Hanwha Ocean (042660) – Daishin | Early Offshore Revenue · Naval Defense Pipeline · Excessive Discount / 2026-07-09 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Fully Booked North America ESS Expected · European IAA Benefits · 1Q Earnings Resilience / 2026-04-02 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] LIG D&A (079550) – Yuanta Securities | 4Q25 Review · Conservative 2026E Guidance · Long-term Structural Growth / 2026-02-19 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 & Rockville Ramp-up · Guidance Upside · 4Q Earnings Concentration / 2026-07-24 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q4 2025 Earnings Presentation / 2026-01-23 IR Room
  • [Research] Celltrion (068270) – DS Investment & Securities | 2nd-Gen Biosimilar Penetration · COGS Ratio Stabilization · Global Capacity Expansion / 2026-05-07 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | LPDDR Demand · Mobile DRAM Tightness · Earnings Growth / 2026-04-24 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Multi-Year LTA · Price Downside Protection · ROE Sustainability / 2026-04-06 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q1 2024 Earnings Presentation / 2024-04-29 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | High-Value Order Expansion · ASP Growth · Earnings Upward Revision / 2026-07-31 Research
  • [Research] Celltrion (068270) – Daishin Securities | New Product Mix · H2 Margin Expansion · New Drug Pipeline / 2026-07-28 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme